{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T02:44:09Z","timestamp":1774925049584,"version":"3.50.1"},"reference-count":10,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"published-print":{"date-parts":[[2003]]},"abstract":"<i>Background:<\/i> Although several immunological abnormalities have been demonstrated in Beh\u00e7et\u2019s disease (BD), the exact mechanism of the inflammatory changes occurring is still unknown. Antigen-presenting cells, such as mononuclear phagocytes, play a major role in the regulation of immune-mediated as well as of non-specific inflammation. <i>Objective:<\/i> To investigate the serum activity of patients with BD on antigen and chemokine expression of human macrophages in vitro. <i>Methods:<\/i> Serum of 15 patients (8 women, 7 men; mean age 33 \u00b1 10 years) with BD was incubated with cultured macrophages isolated from peripheral blood of healthy volunteers. Macrophages maintained in patients\u2019 serum, fetal calf serum with\/without dexamethasone and interleukin (IL)-4 or \u03b3-interferon were investigated for alternative macrophage-activation-associated CC-chemokine 1 (AMAC-1) and IL-8 mRNA expression by Northern blotting. In addition, cytocentrifuge macrophage preparations were stained with monoclonal antibodies against proteins indicating alternative (anti-inflammatory) macrophage activation, such as MS-1 high-molecular-weight protein (MS-1-HMWP), RM3\/1 antigen (CD163) and 25F9, as well as classical (pro-inflammatory) macrophage activation, such as CD11c, class I receptor binding the Fc part of IgG (Fc\u03b3RI: CD64) and class III receptor binding the Fc part of IgG (Fc\u03b3RIII: CD16). <i>Results:<\/i> Macrophages treated with patients\u2019 serum showed neither AMAC-1 expression nor staining with monoclonal antibodies for MS-1-HMWP, CD163 or 25F9. Concomitant treatment with IL-4\/dexamethasone up-regulated significantly the expression of CD163. In contrast, IL-8 mRNA expression and staining for CD11c and CD64 were strongly positive after treatment with serum of patients with BD. CD64 positivity and IL-8 mRNA expression were more prominent in patients with active BD than in patients with inactive disease. <i>Conclusion:<\/i> Taken together, our results indicate that serum of patients with BD induces classical (pro-inflammatory) activation of human peripheral blood macrophages in vitro. Our findings suggest that serum factor(s) may be responsible for inflammatory changes in BD.<\/jats:p>","DOI":"10.1159\/000068888","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T21:05:40Z","timestamp":1050440740000},"page":"225-232","source":"Crossref","is-referenced-by-count":47,"title":["Serum of Patients with Beh\u00e7et\u2019s Disease Induces Classical (Pro-Inflammatory) Activation of Human Macrophages in vitro"],"prefix":"10.1159","volume":"206","author":[{"given":"E.","family":"Alpsoy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Kodelja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Goerdt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.E.","family":"Orfanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ch.C.","family":"Zouboulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2003,4,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910213411707"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000051781"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92643-V"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.15.1.675"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s004030000128"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000018426"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s005990050002"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000018427"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.8.1010"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.4.467"}],"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/68888","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/68888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:39:44Z","timestamp":1745465984000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000068888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003]]},"references-count":10,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2003,7,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000068888","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003]]}}}